How the Fever Tree Makes Its Medicine
For more than two centuries, the cinchona tree has held humanity in its grip. The bark of these Andean evergreens gave us quinine—the first effective treatment for malaria, the compound that allowed European empires to stake their claims in tropical territories, and the bitter flavor still tingling in a glass of tonic water.
Yet despite quinine's outsized role in history, no one understood how the tree itself manufactured it. The chemistry was worked out in the 1940s; the structure solved in 1908; the compound itself isolated in 1820. But the biological factory inside the plant remained a black box.
The Breakthrough
That box has now been opened. A team at the Max Planck Institute for Chemical Ecology, publishing in Nature this March, has identified the complete set of genes and enzymes that cinchona plants use to build quinine and its relatives.
The work resolves one of natural product chemistry's longest-standing gaps—and opens new routes to producing these valuable compounds without harvesting endangered trees.
Mapping the Pathway
The research, led by Blaise Kimbadi Lombe, Tingan Zhou, and Sarah O'Connor, began by tracing cinchona's biosynthetic pathway from an intermediate called corynantheal. Earlier work had established that cinchona alkaloids begin as a condensation of two simpler molecules, but the transformations that followed—converting corynantheal into the distinctive quinoline-quinuclidine scaffold that defines the family—remained entirely unknown.
By feeding isotopically labeled versions of corynantheol to cinchona tissues, the team tracked what the plant did with it. Three intermediates emerged that had never been characterized before.
The first was corynantheol itself—the immediate reduction product of corynantheal.
The second, named cinchonium, proved to be a quaternary ammonium compound never previously detected in cinchona metabolism.
The third was a cyclized form of the long-predicted cinchonaminal intermediate.
Crucially, the researchers showed all three were genuine on-pathway players by re-feeding each labeled compound back to fresh plant tissue and watching it get incorporated into downstream products like cinchonidine and cinchonine.
Enzyme Discovery
With the chemical steps mapped, the hunt for the responsible enzymes combined multiple modern approaches: single-nucleus RNA sequencing to pinpoint which cells were expressing alkaloid pathway genes, comparative transcriptomics across related plant species, and classical protein fractionation.
The most striking discovery came from the enzyme that installs the malonyl group onto corynantheol—malonyl-corynantheol transferase, or MAT. Rather than simply adding a chemical handle, the malonylation sets up a second enzyme, malonyl-corynantheol cyclase (MCC), to perform an unusual cyclization that simultaneously displaces the malonate group and forms the quaternary amine ring of cinchonium.
Both enzymes belong to the BAHD family of acyltransferases, but MCC has evolved a deep binding pocket that orients the substrate precisely for intramolecular attack—a reaction never before documented in plant metabolism.
From cinchonium, a series of oxidations and reductions—catalyzed by enzymes named CiS, CiR, and CiO—convert the intermediate into the quinoline ketones cinchonidinone and cinchoninone, which exist in a tautomeric equilibrium matching the ratio found in the plant.
The final step, reduction of the ketone to yield the mature alkaloids, proved trickier to pin down; the most active candidate enzyme, KR4, was inhibited by other compounds in the tobacco plant used as a heterologous expression host.
Successful Expression
When the researchers assembled the full gene stack in tobacco leaves, the plant successfully manufactured the quinoline alkaloids from a simple precursor.
The pathway accepted modified starting materials too: feeding fluorinated and chlorinated tryptamine analogs yielded corresponding halogenated versions of the final products. The enzymes, it turned out, were promiscuous enough to handle non-native substrates without breaking.
The practical implications are significant. Cinchona bark remains the only commercial source of quinine, and sustainable production has long been a goal. More tantalizing is the possibility of generating novel alkaloid analogs—halogenated derivatives, for instance—that might have improved pharmaceutical properties.
Halogenated quinolines are widely used in medicine, and the ability to biosynthetically produce such compounds opens new avenues for drug discovery.
Evolutionary Insights
What the study reveals about plant biochemistry is equally striking. All the cinchona alkaloid genes cluster in epidermal cells, a different tissue localization than the related Madagascar periwinkle uses for its own monoterpene indole alkaloids.
The malonyltransferase pathway, never before seen in this alkaloid family, appears to have evolved through the functional repurposing of an existing enzyme family. Both MAT and MCC derive from BAHD ancestors, yet they catalyze mechanistically distinct reactions and sit in distant branches of the family tree.
Open Questions
Some questions remain. The enzyme controlling whether the final products carry a carbon-carbon double bond or a single bond at a key position hasn't been identified.
And the KR4 reductase's inhibition in heterologous hosts suggests that finding the native final-step enzyme may require looking elsewhere.
But the core pathway from corynantheol to finished quinoline is now complete—and with it, a mystery that eluded chemists since Napoleon conquered Egypt has finally given way.
Based on: How the fever tree makes its medicine; Max Planck Institute for Chemical Ecology; Nature, March 2024.